Skip to main content
Clinical Trials/NCT01580904
NCT01580904
Completed
Not Applicable

Popular Pharmacy of Brazil: Impact of Pharmaceutical Care in Diabetics Patients

Universidade Estadual da Paraiba1 site in 1 country100 target enrollmentSeptember 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus Type 2
Sponsor
Universidade Estadual da Paraiba
Enrollment
100
Locations
1
Primary Endpoint
Glycated Hemoglobin
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The monitoring of diabetics by the pharmacist may contribute to the effectiveness of drug treatment and to improve their quality of life. This study will measure the impact of pharmacotherapeutic follow-up in diabetic patients. This will be a clinical trial, single blind, controlled, randomized, conducted in two units of pharmacies in Brazil. Only in the intervention group will be held the pharmacotherapeutic follow using a methodology called the practice of pharmaceutical care, which identifies and resolves problems related to drugs. The primary outcome is glycated hemoglobin, and secondary outcomes are baseline glucose, total cholesterol and its fractions (for example LDL), all these measures will be made in the intervention group and control group. Patients will be followed for 24 weeks, and the outcomes will be assessed up to 24 weeks. There will be a confidence interval of 95% and a significance of p <0.05, and will use the Student t test, chi-square analysis of variance (ANOVA) and others if necessary. Expects good results and serve as a model for other researchers.

Registry
clinicaltrials.gov
Start Date
September 2009
End Date
December 2011
Last Updated
9 years ago
Study Type
Interventional
Study Design
Factorial
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Patrícia Trindade Costa Paulo

Impact of Pharmaceutical Care in Diabetics Patients: Clinical Trial Randomized

Universidade Estadual da Paraiba

Eligibility Criteria

Inclusion Criteria

  • Inclusion criteria:
  • patients aged 30 years,
  • diagnosed with type 2 diabetes,
  • to make use of oral antidiabetic agents with or without insulin

Exclusion Criteria

  • those who had infectious diseases during the research
  • missed three consecutive interviews,
  • suspended the hypoglycemic drug and medical order

Outcomes

Primary Outcomes

Glycated Hemoglobin

Time Frame: Up to 24 weeks

average glycated hemoglobin over 24 weeks

Fasting Glycemia

Time Frame: Up to 24 weeks

average fasting glycemia over 24 weeks

Secondary Outcomes

  • Total Cholesterol(Up to 24 weeks)
  • LDL Cholesterol(Up to 24 weeks)

Study Sites (1)

Loading locations...

Similar Trials